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Conversion to eslicarbazepine acetate
monotherapy
A pooled analysis of 2 phase III studies
ABSTRACT
Objective: To assess the efficacy and safety of eslicarbazepine acetate (ESL) monotherapy.
Methods: This post hoc pooled analysis of 2 randomized double-blind studies (093-045 and
-046) included adults with partial-onset seizures medically uncontrolled by 1 or 2 antiepileptic
drugs (AEDs). Following the baseline period (8 weeks), eligible patients were randomized 2:1 to
receive ESL 1,600mg or 1,200 mg once daily for 18 weeks; the primary endpoint was study exit
by meeting predefined exit criteria (signifying worsening seizure control). In each study, treatment
was considered effective if the upper 95% confidence limit for exit rate was lower than the his-
torical control threshold (65.3%).
Results: Pooled exit rates were as follows: ESL 1,600 mg 5 20.6% (95% confidence interval:
15.6%–26.8%); ESL 1,200 mg 5 30.8% (23.0%–40.5%). Use of 2 baseline AEDs or rescue
medication, US location, epilepsy duration $20 years, and higher maximum baseline seizure
frequency were associated with higher exit risks. Median percent reductions in standardized
seizure frequency between baseline and the 18-week double-blind period were as follows: ESL
1,600 mg5 43.2%; ESL 1,200 mg5 35.7%; baseline carbamazepine use was associated with
smaller reductions. Safety profiles were similar between ESL doses.
Conclusions: Exit rates for ESL monotherapy (1,600 mg and 1,200 mg once daily) were lower
than the historical control threshold, irrespective of baseline AED use and region, with no addi-
tional safety concerns identified. Clinical factors and location clearly influence treatment re-
sponses in conversion-to-monotherapy trials.
Classification of evidence: This pooled analysis provides Class IV evidence that for adults with
medically uncontrolled partial-onset seizures, ESL monotherapy is well tolerated and effective.
Neurology® 2016;86:1095–1102
GLOSSARY
AE 5 adverse event; AED 5 antiepileptic drug; CI 5 confidence interval; ESL 5 eslicarbazepine acetate; ITT 5 intent-to-
treat; KM 5 Kaplan–Meier; MADRS 5 Montgomery–Åsberg Depression Rating Scale; POS 5 partial-onset seizure; QOLIE-
31 5 31-item Quality of Life in Epilepsy; SAE 5 serious adverse event; SSF 5 standardized seizure frequency; TEAE 5
treatment-emergent adverse event; UCL 5 upper 95% confidence limit.
Antiepileptic drug (AED) monotherapy for epilepsy compares favorably with polypharmacy,
often with fewer side effects and fewer drug–drug interactions.1,2 There is a need for effective
and well-tolerated AEDs for use in the monotherapy setting.
Eslicarbazepine acetate (ESL) (Aptiom; Sunovion Pharmaceuticals Inc., Marlborough, MA)
is a once-daily oral AED, approved by the US Food and Drug Administration for the treatment
of partial-onset seizures (POS) as monotherapy or adjunctive therapy, and by Health Canada as
adjunctive therapy of POS in patients with epilepsy who are not satisfactorily controlled with
conventional therapy. ESL (Zebinix; BIAL – Portela & Ca., S.A., S. Mamede do Coronado,
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Portugal) is approved by the European Medi-
cines Agency as adjunctive therapy of POS in
adults. Eslicarbazepine, the active metabolite
of ESL, is thought to inhibit sodium currents
by stabilizing the inactivated state of voltage-
gated sodium channels.3
The results of 2 ESL monotherapy studies
(093-045 and 093-046) have been reported
previously.4,5 ESL monotherapy (1,600 mg
and 1,200 mg once daily) was found to be
effective (superior to a historical control) and
well tolerated. A combined analysis of these
studies allowed a more thorough evaluation
of ESL monotherapy; pooling data from iden-
tically designed studies provides greater statis-
tical power for the assessment of treatment
effects in patient subgroups of interest. This
analysis evaluates the relationships between
various factors (including geographic region,
number and type of baseline AEDs, benzodi-
azepine use, and presence of secondarily gen-
eralized seizures) and the efficacy and safety of
ESL monotherapy.
METHODS The study design (including inclusion and exclu-
sion criteria, exit criteria, and randomization technique) and sta-
tistical methods (including sample size determination) were
identical for both studies.4,5
Classification of evidence. The primary research question was
whether the rate of study exit (by meeting predefined exit criteria
signifying worsening seizure control) for patients taking ESL
(1,600 mg or 1,200 mg) was lower than the historical control
threshold. This pooled analysis provides Class IV evidence that
for adults with medically uncontrolled POS, ESL monotherapy
is well tolerated and effective.
Standard protocol approvals, registrations, and patient
consents. The 2 studies (093-046 [NCT01091662] and 093-
045 [NCT00866775], both registered at ClinicalTrials.gov) were
conducted between 2009 and 2013 at sites in the United States,
Canada, Bulgaria, Serbia, the Ukraine, and the Czech Republic,
in accordance with the principles of the Declaration of Helsinki,
the International Conference on Harmonisation guidelines, and
all national, state, and local laws of the pertinent regulatory
authorities. Approval was received from the relevant independent
ethics committees/institutional review boards, and all patients
provided informed consent.
Patients. Patients aged 16 to 70 years with a diagnosis of
localization-related (focal) epilepsy (defined by the International
League Against Epilepsy, 1981)6 and a history of POS were
eligible for study participation if they satisfied the following
criteria: no confounding factors (e.g., psychogenic nonepileptic
spells, syncope, progressive structural abnormality); documented
EEG recording consistent with POS;$4 POS during the 8 weeks
before screening, with no seizure-free period$4 weeks; treatment
with stable doses of 1 or 2 AEDs in the 4 weeks before screening
(if receiving 2 AEDs at screening, only 1 could be a sodium
channel blocker [i.e., phenytoin, carbamazepine, oxcarbazepine,
or lamotrigine] and only 1 could be in the upper dose range
[greater than approximately two-thirds of its defined daily
dose]7); and no additional/potential health complications
(elderly patients [65–70 years] only).
Study design. After an 8-week baseline period, eligible patients
were randomized 2:1 to receive oral ESL (1,600- or 1,200-mg
tablets once daily), and began the 18-week, double-blind
treatment period (2-week ESL titration, 6-week AED
conversion [concomitant AEDs withdrawn], 10-week ESL
monotherapy). Eligible patients then had the option to enter an
open-label extension study (long-term data will be published
separately); alternatively, patients entered a 1-week dose-
tapering period and left the study (figure e-1 on the Neurology®
Web site at Neurology.org).
Individual patient data from the double-blind phases of the 2
trials (045 and 046) were pooled and analyzed.
Assessments. Primary endpoint. Seizure data were obtained
using seizure diaries, completed daily by the patients or their care-
givers throughout the study. The primary efficacy endpoint was
study exit by meeting $1 of 5 prospectively defined exit criteria
(signifying worsening seizure control), between the start of the
AED conversion period and the end of the monotherapy period.
Secondary endpoints. The key secondary efficacy endpoint
was the percentage of patients who achieved seizure freedom
throughout the 10-week monotherapy period. Other prospec-
tively specified secondary efficacy endpoints included change in
standardized seizure frequency (SSF) (per 28 days) between
baseline and the 18-week double-blind treatment period;
responder rate (proportion of patients with $50% reduction in
SSF vs baseline); change in 31-item Quality of Life in Epilepsy
(QOLIE-31) total scores; change in Montgomery–Åsberg
Depression Rating Scale (MADRS) scores; and completion rates
(proportions of patients completing the 18-week treatment and
10-week monotherapy periods).
Safety and tolerability. Investigators recorded adverse events
(AEs) at each clinic visit. AEs were coded using the Medical Dic-
tionary for Regulatory Activities, version 13.1. Treatment-
emergent AEs (TEAEs) were defined as AEs that occurred on
or after the first dose of study drug. Serious AEs (SAEs) were
reported separately; classification of AEs as “serious” was at the
judgment of the investigators. Summary statistics for TEAEs were
calculated for each study period (titration, AED conversion, and
ESL monotherapy periods).
Statistical analyses. Both studies used a historical control com-
parator, as proposed by French et al.8 The historical control exit
rate was determined from the placebo/pseudo-placebo groups of
8 historical conversion-to-monotherapy trials. The lower bound
of the 95% prediction interval of the overall exit rate (i.e., 65.3%
at 112 days)9 was used as the exit threshold for a scenario
involving a single study. Similarly to the individual studies,
pooled cumulative exit rates and 95% confidence intervals
(CIs) at 112 days were estimated using Kaplan–Meier (KM)
methodology for each ESL treatment group. Methods for
censoring and patient reassignment have been previously
reported.4,5
Exit rates and 95% CIs were estimated for patient subgroups
defined by baseline AED use (those AEDs used by $15% of
patients) and region (US vs non-US). Effects of subgroup factors
were also evaluated separately, using a Cox proportional hazards
regression model.
A worst-case scenario analysis was conducted to evaluate the
potential confounding effect of benzodiazepine use: patients who
took benzodiazepine derivatives during the AED conversion
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period, after the first dose of study medication, were considered to
have met the study exit criteria at the time of use. The relation-
ship between QOLIE-31 overall score and reduction in SSF from
baseline was evaluated via Pearson correlation.
All statistical procedures were performed using SAS version
9.2 (SAS Institute, Cary, NC). All statistical tests were 2-sided.
Study populations. The pooled intent-to-treat (ITT) popu-
lation comprised all randomized patients in the 2 trials who
received$1 dose of study drug. The ITT population was used to
evaluate patient disposition, baseline demographics and charac-
teristics of the overall population, and safety outcomes. Efficacy
analyses and comparisons of baseline demographics and charac-
teristics between US and non-US patients used the pooled effi-
cacy population (i.e., all ITT patients who entered the AED
conversion period).
RESULTS Patients. The ITT population comprised
365 patients (ESL 1,600 mg, n 5 242; ESL 1,200
mg, n 5 123; figure e-2). Baseline demographic and
clinical characteristics were generally well balanced
between dose groups (table e-1) and comparable to
those of the historical control comparator group
(Jacobson et al.,5 2015 [table S2]).
The efficacy population comprised 332 patients
(ESL 1,600 mg, n 5 218; ESL 1,200 mg, n 5
114; US, n 5 211; non-US, n 5 121). There were
some notable differences in demographics and clinical
characteristics between the US and non-US sub-
groups (table 1). The US subgroup had a longer
median duration of illness, more levetiracetam use,
and less valproic acid and lamotrigine use, as well as
higher proportions of obese individuals, and black,
Asian, and Hispanic patients, than the non-US sub-
group. Compared with the non-US subgroup, the US
subgroup also had higher maximum 2- and 28-day
seizure rates and more benzodiazepine use during the
baseline period.
Efficacy. Primary endpoint. In the individual studies
(045 and 046), the upper 95% confidence limits
(UCLs) of exit rates for both ESL doses were
lower than the historical control threshold
(65.3%), indicating drug efficacy.4,5 The pooled
KM-estimated exit rates at 112 days were 20.6%
(95% CI: 15.6%–26.8%) for ESL 1,600 mg
and 30.8% (23.0%–40.5%) for ESL 1,200 mg
(figure 1).
Secondary analyses of the primary endpoint. US vs non-US
patients. The KM-estimated exit rates for the US sub-
group were greater than those for the non-US sub-
group (figure 2A). Cox proportional hazard
regression analysis confirmed that US patients
were significantly more likely to exit the study
(p , 0.001; figure 2C). The time to exit for US
patients exhibited a dose-response relationship; the
rate was lower with ESL 1,600 mg vs 1,200 mg.
For US patients taking 2 baseline AEDs, or with
secondarily generalized seizures before or during
the baseline period, the difference in exit rates
between dose groups was particularly marked.
For all 4 subgroups (US and non-US patients tak-
ing ESL 1,600 and 1,200 mg), the UCLs of the
exit rates were lower than the 65.3% historical
control threshold.
Baseline AEDs.KM-estimated exit rates were also cal-
culated for subgroups defined by baseline AED use
(for AEDs taken by $15% of patients; figure 2B).
Use of carbamazepine (n 5 91), lamotrigine (n 5
49), levetiracetam (n 5 82), and valproic acid (n 5
66) at baseline did not have statistically significant
effects on risk of exit (figure 2C).
Overall, 31.0% of patients were taking 2 AEDs
during the baseline period. The exit risk was signifi-
cantly higher for patients taking 2 baseline
AEDs (vs 1; figure 2C). In addition, exit risk was
Table 1 Selected demographics and baseline clinical characteristics for the
pooled efficacy population (US and non-US subgroups)
US (n 5 211) Non-US (n 5 121)
Patient demographics
Race, %
White 74.4 99.2
Black or African American 11.8 0.0
Asian 1.9 0.8
Hispanic ethnicity, % 16.6 0.0
Weight, kg, mean (SD) 88.3 (26.0) 72.9 (14.3)
BMI >30 kg/m2, % 46.4 10.7
Clinical characteristics
Duration of epilepsy, y, median 17.0 11.0
Duration of epilepsy ‡20 y, % 43.6 28.1
AEDs used by ‡15% of patients,a %
Carbamazepine 26.5 28.9
Lamotrigine 11.8 19.8
Levetiracetam 31.8 12.4
Valproic acid 10.9 35.5
Taking 1 AED,a % 68.7 69.4
Partial seizures evolving to secondarily
generalized seizures, %
25.1b 39.7c
Maximum consecutive 2-d seizure
rate, mean (SD)
3.7 (2.6)b 2.2 (1.3)c
Maximum consecutive 28-d seizure
rate, mean (SD)
13.4 (9.1)b 10.0 (7.2)c
Maximum consecutive 28-d seizure
rate >15/mo, %
31.3b 14.9c
Benzodiazepines used, % 10.0 2.5
Abbreviations: AED 5 antiepileptic drug; BMI 5 body mass index; US 5 United States.
Percentages are calculated based on the number of patients with available data in the
efficacy population in each subgroup.
a An AED was considered to be used at baseline if it was started at any time before the first
dose of study drug and continued into the titration period.
b n 5 210.
c n 5 120.
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significantly lower for patients taking phenytoin at
baseline (vs those not taking phenytoin; p 5
0.049), although the sample size was small (only 30
patients were taking baseline phenytoin).
Benzodiazepine use. Patients who used benzodiaze-
pines had a higher risk of study exit (figure 2C).
Approximately 7.8% of patients had not used ben-
zodiazepines before randomization but used them
during the 18-week treatment period. In a sensitiv-
ity analysis of the primary endpoint, in which pa-
tients who used benzodiazepines after the start of
the AED conversion period, but not before the first
dose of study medication, were deemed to have met
the exit criteria, the UCLs of exit rates for both ESL
dose groups were also lower than the 65.3%
historical control threshold (1,600 mg 5 24.2%
[95% CI: 18.9%–30.8%]; 1,200 mg 5 32.6%
[24.6%–42.4%]).
Disease characteristics. Exit risk was also found to be
higher for patients with a duration of epilepsy
$20 years, for patients with a higher baseline
seizure rate (maximum consecutive 2-day rate),
for those who used vagal nerve stimulation during
baseline, and for those who used rescue medication
(figure 2C).
Secondary endpoints.The proportion of patients who
achieved seizure freedom during the entire 10-week
monotherapy period was similar for the 2 ESL dose
groups (ESL 1,600 mg 5 8.7% [95% CI: 5.3%–
13.3%]; ESL 1,200 mg5 7.9% [CI: 3.7%–14.5%]).
Seizure frequency was calculated as SSF per 28
days. The median percent reduction from baseline
in SSF for the 18-week treatment period was
43.2% with ESL 1,600 mg and 35.7% with ESL
1,200 mg (figure 3); for the 10-week monotherapy
period, the median percent reduction was 46.3% and
47.1% with ESL 1,600 mg and 1,200 mg, respec-
tively. Responder rates (proportion of patients with
$50% reduction in SSF) during the 18-week treat-
ment period were 42.7% for ESL 1,600 mg and
36.0% for ESL 1,200 mg. Reductions in seizure fre-
quency occurred in patients taking different AEDs at
Figure 1 Kaplan–Meier analysis of exit rates (efficacy population): Pooled population (A) and individual studies
and pooled population (B)
CI 5 confidence interval; ESL 5 eslicarbazepine acetate; QD 5 once-daily; US 5 United States.
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Figure 2 Subgroup analyses of exit rates (pooled efficacy population): Influence of geographic region on exit
rate (US vs non-US regions) (A), of baseline AED use (AEDs used by ‡15% of patients) on exit rate
(B), and of patient characteristics on risk of study exit (pooled efficacy population) (C)
Note that for age, baseline body weight, and maximum 2- or 28-day seizure rate, the hazard ratio is displayed for a single
unit change; otherwise, it is shown for the referenced group compared to those without the stated factor. VPA included all
dosage forms combined unless otherwise stated (including VPA, sodium valproate, divalproex sodium, etc.). aBZD deriva-
tives used before study treatment (prior), after initiation of the AED conversion period as rescue or emergency medication
(after), or only after study treatment (not prior, after). AED5 antiepileptic drug; B/L5 baseline; BZD5 benzodiazepine; CBZ
5 carbamazepine; CI 5 confidence interval; CP 5 complex partial seizure; duration 5 duration of epilepsy; ESL 5 eslicar-
bazepine acetate; LEV 5 levetiracetam; LTG 5 lamotrigine; OXC 5 oxcarbazepine; PHT 5 phenytoin; SGTC 5 secondarily
generalized tonic-clonic seizures (also referred to as complex partial seizures with secondary generalization); sz 5 seizure;
TOP 5 topiramate; US 5 United States; VNS 5 vagal nerve stimulator; VPA 5 valproic acid.
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baseline, but the magnitude of reduction was less for
patients who were taking carbamazepine at baseline
than for those who were not (figure 3).
For patients who continued into the monotherapy
period, overall QOLIE-31 scores increased between
baseline and the end of the monotherapy period
(ESL 1,600 mg, 5.7-point median increase; ESL
1,200 mg, 3.3 point median increase; calculated for
the 252 patients who had QOLIE-31 scores for both
the baseline and monotherapy periods). Of note,
there was a statistically significant correlation (p 5
0.001) between reduction in SSF from baseline and
the increase in overall QOLIE-31 score. Similarly,
MADRS total scores decreased by a median of 1 point
with ESL 1,600 mg and were unchanged with ESL
1,200 mg (calculated for the 267 patients who had
MADRS scores for both periods).
Completion rates for the 18-week treatment
period were 71.6% (95% CI: 65.1%–77.4%) for
ESL 1,600 mg and 61.4% (51.8%–70.4%) for ESL
1,200 mg. For the 10-week monotherapy period,
completion rates were 86.2% (95% CI: 80.3%–
90.9%) for ESL 1,600 mg and 75.3% (65.2%–
83.6%) for ESL 1,200 mg.
Safety. TEAEs reported for $5% of patients during
each treatment period are shown in table 2. Head-
ache, dizziness, somnolence, and fatigue were the
most frequently reported TEAEs. There was no clear
relationship between incidence of these TEAEs and
ESL dose. Depression was reported in 2.5% and
0.8% of patients taking ESL 1,600 mg and 1,200
mg, respectively, and “suicidal ideation” in 2 pa-
tients (1.6%) taking ESL 1,200 mg. Serum sodium
#125 mEq/L was recorded in 7 patients taking ESL
1,600 mg (2.9%) and 5 patients taking ESL 1,200
mg (4.1%). TEAEs led to discontinuation in 15.3%
and 8.1% of patients taking ESL 1,600 mg and
1,200 mg, respectively. Events leading to discontin-
uation included hyponatremia (1.4%), skin and sub-
cutaneous tissue disorders (ESL 1,600 mg, 2.9%;
ESL 1,200 mg, 0.8%), and drug rash with eosino-
philia and systemic symptoms (ESL 1,600 mg,
1 patient).
During the 18-week treatment period, SAEs
occurred in 21 patients (5.8% overall: ESL 1,600
mg, 6.6%; ESL 1,200 mg, 4.1%). The most frequent
SAEs were hyponatremia (ESL 1,600 mg, 1.2% [3
patients]; ESL 1,200 mg, 0%), complex partial seiz-
ures (0.8% [2 patients]; 0%), and partial seizures with
secondary generalization (0.4% [1 patient]; 0.8%
Figure 3 Median percentage reduction in standardized seizure frequency overall and by baseline AED
Median percentage reduction in standardized seizure frequency (seizures per 28 days; between baseline and the 18-week treatment period) overall and by
baseline AED (for AEDs used by $15% of patients during baseline; efficacy population). AED 5 antiepileptic drug; CBZ 5 carbamazepine; ESL 5 eslicar-
bazepine acetate; LEV 5 levetiracetam; LTG 5 lamotrigine; VPA 5 valproic acid.
Table 2 Incidence of TEAEsa during different treatment periods (pooled ITT
population)
TEAE
ESL 1,200 mg
once daily, n (%)
ESL 1,600 mg
once daily, n (%)
Titration period n 5 123 n 5 242
Dizziness 18 (15) 35 (14)
Headache 8 (7) 32 (13)
Somnolence 7 (6) 23 (10)
Fatigue 12 (10) 18 (7)
Taper/conversion period n 5 114 n 5 218
Headache 12 (11) 27 (12)
Dizziness 8 (7) 24 (11)
Monotherapy period n 5 93 n 5 181
Headache 10 (11) 21 (12)
Abbreviations: ESL 5 eslicarbazepine acetate; ITT 5 intent-to-treat; TEAE 5 treatment-
emergent adverse event.
aOccurring in $5% of patients in both dose groups.
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[1 patient]). There were no cases of second- or third-
degree atrioventricular block; cardiac SAEs were re-
ported in 2 patients taking ESL 1,200 mg (1.6%):
1 had cardiogenic shock and 1 had atrial flutter
(before the first ESL dose). There was 1 death in
study 045 (ESL 1,200-mg treatment arm), caused
by multiple injuries due to a car accident of unknown
cause, and 1 pretreatment seizure-related death in
study 046 (during the baseline period).
DISCUSSION The findings of this analysis extend
those of the individual ESL monotherapy studies
(045 and 046).4,5 The pooled analysis provides more
precise estimates of the overall treatment effect and
higher statistical power to examine the effects of sub-
group factors.
Factors statistically associated with higher exit
risk (failed transition to ESL monotherapy) are
shown in figure 2C; as several of these factors are
often indicators of more severe epilepsy, the greater
propensity for exit is not surprising. In future studies
(and perhaps clinical practice), when transitioning to
ESL monotherapy, it may be beneficial to use a lon-
ger tapering schedule to reduce the risk of seizure
exacerbation in individuals with risk factors. In addi-
tion, patients from the United States were signifi-
cantly more likely to exit the studies. A lamotrigine
XR monotherapy trial also found that KM-estimated
exit rates were higher in US vs non-US patients.9 In
contrast, a lacosamide study found a lower exit rate
in North American patients vs patients from other
regions.10 The observed difference in exit rates may
be related to differences between regions in clinical
practice, patient characteristics, or placebo-response
rate, as well as economic or cultural influences. For
example, the use of newer-generation AEDs was
more prevalent among US patients. As US patients
had longer duration of illness and more frequent
seizures than non-US patients, they may have had
more severe epilepsy and so were at greater risk of
study exit.
Although the exit rate was numerically higher
for patients who were taking carbamazepine at
baseline vs those taking other AEDs, the UCLs
for both ESL dose groups were below the 65.3%
threshold. Similarly, patients who converted from
carbamazepine to monotherapy with other AEDs
(pregabalin, valproate, topiramate, felbamate, ox-
carbazepine, tiagabine, or rufinamide) had an
increased hazard rate for study exit (8.0%).8 Hence,
the above finding may not be attributable to any
similarities between carbamazepine and ESL, but
could be related to the withdrawal of carbamaze-
pine. In the current study, patients who converted
from carbamazepine also had less marked reduc-
tions in seizure frequency than those who
converted from other commonly used background
AEDs; the reason for this remains unclear.
The appropriate use of a historical control com-
parator is based on the concept that there are no sub-
stantive differences in population characteristics
between the current studies and the historical control,
or that any population differences do not affect exit
rates. It is of note that the CIs for the ESL 1,200
mg exit rate did not overlap between studies 045
and 046, suggesting that the study population influ-
enced exit rates in these trials. However, exit rates
for both dose groups in these studies were lower than
the rate for the historical control.
Patients were diagnosed using the 1981 version of
the International League Against Epilepsy classifica-
tion.6 Although more recent versions exist,11 the
1981 classification was used to ensure consistency with
other AED trials. As the 1981 guidelines are still used
frequently in clinical practice, we are confident that the
population remains relevant to today’s patients.
The safety profiles of ESL 1,600 mg and 1,200 mg
were similar and there were no incidences of sudden
unexpected death in epilepsy during ESL therapy.
No new safety findings of concern were identified
in this pooled analysis.
Exit rates for patients taking ESL (1,600 mg and
1,200 mg once daily) monotherapy were lower than
the historical control threshold, irrespective of baseline
AED use and region, and ESL was well tolerated. The
potential effects of clinical and demographic factors on
patient outcomes should be taken into consideration
when designing future monotherapy studies. Further
evaluation of the effect of baseline AED use on treat-
ment response is also needed, given the difference in
outcomes between patients who were taking baseline
phenytoin and carbamazepine in this analysis.
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